BioNexus Gene Lab Corp.

General ticker "BGLC" information:

  • Sector: Industrials
  • Industry: Trading Companies & Distributors
  • Capitalization: $7.2M (TTM average)

BioNexus Gene Lab Corp. follows the US Stock Market performance with the rate: 36.8%.

Estimated limits based on current volatility of 3.7%: low 4.18$, high 4.51$

Factors to consider:

  • Total employees count: 18 as of 2022
  • Top business risk factors: Limited operating history, Economic downturns and volatility, Dependence on financing markets, Geopolitical risks, Regulatory and compliance
  • Current price 22.3% above estimated high
  • Earnings for 9 months up through Q3 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [1.38$, 3.54$]
  • 2025-12-31 to 2026-12-31 estimated range: [1.38$, 3.35$]

Similar symbols

Short-term BGLC quotes

Long-term BGLC plot with estimates

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $10.93MM $9.77MM $9.51MM
Operating Expenses $11.22MM $12.36MM $11.08MM
Operating Income $-0.29MM $-2.59MM $-1.57MM
Non-Operating Income $-0.01MM $-0.01MM $-0.02MM
Interest Expense $0.01MM $0.01MM $0.02MM
R&D Expense $0.00MM $0.05MM $0.05MM
Income(Loss) $-0.30MM $-2.61MM $-1.59MM
Taxes $0.05MM $0.02MM $0.00MM
Profit(Loss)* $-0.36MM $-2.63MM $-1.60MM
Stockholders Equity $6.67MM $9.66MM $8.32MM
Inventory $0.98MM $1.14MM $1.39MM
Assets $8.74MM $11.40MM $10.43MM
Operating Cash Flow $0.55MM $-1.30MM $-2.23MM
Capital expenditure $0.05MM $0.15MM $0.23MM
Investing Cash Flow $-0.45MM $-0.38MM $0.42MM
Financing Cash Flow $0.11MM $5.75MM $0.14MM
Earnings Per Share** $-0.25 $-1.53 $-0.90

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.